Acurx Pharmaceuticals, Inc. (ACXP)
| Market Cap | 7.23M -7.4% |
| Revenue (ttm) | n/a |
| Net Income | -7.50M |
| EPS | -3.89 |
| Shares Out | 3.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250,468 |
| Open | 2.060 |
| Previous Close | 1.930 |
| Day's Range | 1.970 - 2.220 |
| 52-Week Range | 1.326 - 21.000 |
| Beta | -2.09 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+762.94%) |
| Earnings Date | May 11, 2026 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ACXP stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 762.94% from the latest price.
News
Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026
Initiated a pivotal rCDI trial for ibezapolstat, leveraging strong phase II results and new FDA guidance that may allow single pivotal trials. Cash position improved to $9.3M, with reduced expenses and new capital raised to fund ongoing clinical programs.
Acurx Pharmaceuticals Quarterly report: Q1 2026
Acurx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Acurx Pharmaceuticals Earnings release: Q1 2026
Acurx Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics fo...
Acurx files to sell 1.65M shares of common stock for holders
16:17 EDT Acurx (ACXP) files to sell 1.65M shares of common stock for holders
Acurx files to sell 1.3M shares of common stock for holders
16:18 EDT Acurx (ACXP) files to sell 1.3M shares of common stock for holders
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with m...
Acurx Pharmaceuticals Registration statement: Registration filing
Acurx Pharmaceuticals filed a registration statement on May 4, 2026, providing details about a securities offering with the SEC.
Acurx Pharmaceuticals Registration statement: Registration filing
Acurx Pharmaceuticals filed a registration statement on May 4, 2026, providing details about a securities offering with the SEC.
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for ...
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new clas...
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Ac...
Acurx announces $7.1M registered direct offering priced at-the-market
Acurx (ACXP) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock at a purchase price…
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Ac...
New to The Street announce re-signing of Acurx Pharmaceuticals
New to The Street announces the re-signing of Acurx (ACXP) Pharmaceuticals. The renewed agreement extends a multi-year strategic media partnership between New to The Street and Acurx, continuing a mul...
Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
Acurx (ACXP) Pharmaceuticals announced that the Korean Intellectual Property Office has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of us...
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecu...
Acurx price target lowered to $10 from $20 at Alliance Global
Alliance Global lowered the firm’s price target on Acurx (ACXP) to $10 from $20 and keeps a Buy rating on the shares following the Q4 report. The firm pushed back…
Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025
Ibezapolstat advanced with strong phase II results and a new rCDI trial launching in late 2026, supported by improved financials and a strengthened patent position. Lower expenses and ongoing funding initiatives position the company for pivotal trials and potential regulatory acceleration.
Acurx Pharmaceuticals Earnings release: Q4 2025
Acurx Pharmaceuticals released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
Acurx Pharmaceuticals Annual report: Q4 2025
Acurx Pharmaceuticals has published its Q4 2025 annual report on March 13, 2026.
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
Acurx Pharmaceuticals ($ACXP) is having a record-breaking week after the company announced a major update for its lead drug, ibezapolstat. The stock has exploded by over 218% in just the…
Acurx announces new ibezapolstat clinical trial program
Acurx (ACXP) Pharmaceuticals announced that it will conduct a new clinical trial in patients with recurrent C. difficile Infection while its program in the broader CDI patient population is ready…